Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQICTG)

• Drug Name: SAR444419 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Inflammation	1A00-CA43.1	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMQICTG

Molecule-Related Drug Atlas

Drug(s) Targeting Tumor necrosis factor (TNF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[2]
Nafamostat	DMU1XOD	Pancreatitis	DC31-DC34	Approved	[3]
Pentoxifylline	DMU3DNC	Alcoholic hepatitis	DB94.1	Approved	[4]
Lenalidomide	DM6Q7U4	Adult T-cell leukemia/lymphoma		Approved	[5]
Enbrel	DM7RNP3	Arthritis	FA20	Approved	[6]
Golimumab	DMHZV7X	Psoriatic arthritis	FA21	Approved	[7]
Certolizumab	DM5CL9Z	Rheumatoid arthritis	FA20	Approved	[8]
Etanercept	DMCV109	Arthritis	FA20	Approved	[9]
Adalimumab	DMQMV1B	Crohn disease	DD70	Approved	[10]
Infliximab	DMH7OIA	Crohn disease	DD70	Approved	[11]

Drug(s) Targeting Interleukin-6 (IL6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Siltuximab	DMGEATB	Anemia	3A00-3A9Z	Approved	[12]
Sirukumab	DMK8AQP	Cutaneous lupus erythematosus	EB5Z	Phase 3	[13]
Olokizumab	DM4Z9QI	Rheumatoid arthritis	FA20	Phase 3	[14]
Ziltivekimab	DME841B	Heart failure	BD10-BD13	Phase 3	[15]
RG6179	DMO1VP9	uveitic macular edema	9B78	Phase 3	[16]
PF-04236921	DM826SW	Crohn disease	DD70	Phase 2	[13]
Clazakizumab	DM6ZOUV	Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2 Trial	[13]
CDP-6038	DM3YB2C	Rheumatoid arthritis	FA20	Phase 2	[17]
ALD-518	DMPWSBL	Psoriatic arthritis	FA21	Phase 2	[17]
YSIL6	DM0K8U7	Crohn disease	DD70	Phase 2	[18]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-6 (IL6)	TTT1V78	IL6_HUMAN	Not Available	[1]
Tumor necrosis factor (TNF)	TTF8CQI	TNFA_HUMAN	Not Available	[1]

References

• [1] Clinical pipeline report, company report or official report of Sanofi
• [2] Efficacy of different thalidomide regimens for patients with multiple myeloma and its relationship with TNF-alpha level. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Dec;16(6):1312-5.
• [3] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [4] Targeted therapies in myelodysplastic syndromes: ASH 2003 review. Semin Hematol. 2004 Apr;41(2 Suppl 4):13-20.
• [5] Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007351.
• [6] Oral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes : a potential treatment for aseptic loose... J Bone Joint Surg Am. 2001 Jul;83(7):1057-61.
• [7] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [8] Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
• [9] The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72.
• [10] Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation. J Eur Acad Dermatol Venereol. 2009 Dec;23(12):1394-7.
• [11] Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2008 Jun;4(6):300-9.
• [12] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Ann Rheum Dis. 2014 September; 73(9): 1607-1615.
• [15] IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021 May 29;397(10289):2060-2069.
• [16] Clinical pipeline report, company report or official report of Roche
• [17] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [18] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020380)